All in a muddle
Article Abstract:
Prana Biotechnology the Alzheimer's Disease research company had informed the Australian Stock Exchange that further development of the drug Clioquinol is not warranted due to risk of side effects. This has come as a huge blow to the company's investors, scientists and management.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Generic drug frenzy
Article Abstract:
The reasons behind the growth of competition in Australian generic drug business are examined.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Protel races on to a wider circuit. Drug frenzy. Dollar prophets
- Abstracts: AGL tries a new bulb. Primed for profit. Foodland falters
- Abstracts: Bulls are back. Green light for bulls. Bulls take charge
- Abstracts: Wall Street cracks. American influence. Stay in the comfort zonec
- Abstracts: A Bollinger bubble? Moving up. Easy does it